Oligodendroglioma - Pipeline Review, H2 2020

September 2020 | 175 pages | ID: OE358DFEAECEN
Global Markets Direct

Abstracts

Oligodendroglioma - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2020, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.
Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 7, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Phase 0 stages comprises 2, 2 and 1 molecules, respectively.
Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Oligodendroglioma - Overview
Oligodendroglioma - Therapeutics Development
Oligodendroglioma - Therapeutics Assessment
Oligodendroglioma - Companies Involved in Therapeutics Development
Oligodendroglioma - Drug Profiles
Oligodendroglioma - Dormant Projects
Oligodendroglioma - Discontinued Products
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Oligodendroglioma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Target, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Oligodendroglioma - Pipeline by Agios Pharmaceuticals Inc, H2 2020
Oligodendroglioma - Pipeline by Alfasigma SpA, H2 2020
Oligodendroglioma - Pipeline by AngioChem Inc, H2 2020
Oligodendroglioma - Pipeline by Astellas Pharma Inc, H2 2020
Oligodendroglioma - Pipeline by Bayer AG, H2 2020
Oligodendroglioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
Oligodendroglioma - Pipeline by Bristol-Myers Squibb Co, H2 2020
Oligodendroglioma - Pipeline by CDG Therapeutics Inc, H2 2020
Oligodendroglioma - Pipeline by Eli Lilly and Co, H2 2020
Oligodendroglioma - Pipeline by GtreeBNT Co Ltd, H2 2020
Oligodendroglioma - Dormant Projects, H2 2020
Oligodendroglioma - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Oligodendroglioma, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Agios Pharmaceuticals Inc
Alfasigma SpA
AngioChem Inc
Astellas Pharma Inc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
CDG Therapeutics Inc
Eli Lilly and Co
GtreeBNT Co Ltd
Immatics NV
Ipsen SA
Nascent Biotech Inc
Northwest Biotherapeutics Inc
Pfizer Inc
Taiho Oncology Inc
TheraBiologics Inc